Envision Saint John: The Regional Growth Agency ’s Post

Why Greater Seattle is a Top Place for Innovation in Healthcare and Life Sciences https://lnkd.in/gYSvzfhV Seattle-based Swedish Health Services (Swedish) completed its 500th  MitraClip procedure nearly one year ago, and the 10-year program is now one of the top five in the U.S. Swedish’s MitraClip program is one of many innovative life science projects happening in Washington state’s Greater Seattle region. In fact, a recent report from CBRE ranked the city one of the top 10 life science clusters across America. The continued growth and innovation of Seattle’s life sciences has strengthened the state’s economy. Life Science Washington found that the industry holds an economic impact of over $35 billion and currently employs over 44,000 people. “Whether it’s academic and research institutions, places like the Fred Hutchinson Cancer Center or the many dynamic companies continuing to innovate in the life sciences space, this industry has many opportunities to thrive in this region,” said Dr. Elizabeth Wako, president and CEO of Swedish. “The strong ecosystem also… Click here to view original post Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

We are thrilled to announce the release of our latest video, which dives into the details of the DECISION project - a European research consortium, aiming to enhance our understanding of decompensated cirrhosis and acute-on-chronic liver failure at a systems level. 🎥 Join in, as project partners discuss their roles within the project and emphasise the importance of collaboration in advancing scientific research. Learn more about the upcoming clinical trial and the role and representation of patients within DECISION. Get to know our speakers: Pierre-Emmanuel Rautou, scientific coordinator of DECISION, INSERM, Greater Paris University Hospitals - AP-HP, European Foundation for the Study of Chronic Liver Failure (EF CLIF) Sara Palomino Echeverría, researcher patient stratification team, Navarrabiomed, biomedical research centre CARACENI Paolo, Leader of the #COMBATtrial, ALMA MATER STUDIORUM UNIVERSITÀ DI BOLOGNA Pr. Isabelle Durand-Zaleski, Leader Health Economics, Greater Paris University Hospitals - AP-HP Veronika Všetíčková, Patient Representative, European Liver Patients' Association - ELPA   🔍 Watch the full video here or on YouTube: https://lnkd.in/dxzURBMx 📲 Follow us here on LinkedIn to stay informed about the project progress and the latest developments in scientific research on decompensated cirrhosis.   #Cirrhosis #ACLF #Hepatology #DecompensatedCirrhosis #MedicalResearch #Horizon2020

"Breaking through- My Life in science" by Katalin Karikó was my last read of 2023 and it couldn't have been better. A perfect book to start the new year on a high note. As a new mom, I listened the audio book while night nursing sessions. I related to various parts of the book specially 1. The difference in research work culture in Europe and USA 2. The feeling when Katalin had Susan and how she navigated the early child care balancing her science. Here are some key takeaways that I believe are worth sharing: 1️⃣ Persistence Pays Off: Katalin Kariko's journey is a testament to the power of perseverance. Despite facing setbacks and skepticism, she persisted in her research on mRNA, ultimately paving the way for transformative breakthroughs in medicine. 2️⃣ Innovation Against Odds: The book underscores the importance of thinking outside the box and pursuing innovative ideas, even when faced with challenges. Kariko's unconventional approach has reshaped our understanding of mRNA and its applications. 3️⃣ Collaboration is Key: "Breaking Through" highlights the significance of collaboration in scientific research. Kariko's work wouldn't have been possible without the collective efforts of a dedicated team. The power of collaboration is evident in the success of mRNA technology. 4️⃣ Impact on Medicine: The book sheds light on how mRNA technology has the potential to revolutionize medicine. From vaccines to personalized therapies, the applications are vast and hold the promise of addressing previously untreatable diseases. 5️⃣ Scientific Communication Matters: Effective communication is crucial in the world of science. Kariko's ability to communicate her ideas and findings played a pivotal role in garnering support for her research and overcoming obstacles. 6️⃣ Ethical Considerations: "Breaking Through" prompts us to reflect on the ethical implications of scientific advancements. As we celebrate progress, it's essential to engage in thoughtful discussions about responsible and equitable use of emerging technologies. 🌐 I highly recommend "Breaking Through" to anyone interested in the intersection of science, innovation, and the future of medicine. It's a captivating journey that not only educates but also inspires. Let's continue to support and celebrate pioneers like Katalin Karikó who are making a profound impact on our world. #BreakingThrough #mRNA #Innovation #Science #Medicine #KatalinKariko

NCID Monthly Research Meeting – Bringing People Together, Bridging Science and Medicine   This month’s research meeting features the awardees of the NMRC Open Fund - Large Collaborative Grant (OF-LCG) who will share on their project outcomes and experiences. The OF-LCG involves multidisciplinary teams and the scheme supports patient-centric translational research, underpinned by basic and/or applied research. Date: 15 Sep 2023 (Friday) Time: 11am to 12pm Register at: https://lnkd.in/grcsDxke   Refer to the poster below for more information.   #research #healthcare #medicine #science

Pre-announcement of the Nano and advanced technologies for disease prevention, diagnostic and therapy (NANOTECMEC) Call The aims of the call are: – to support translational research projects that combine innovative approaches in the field of nanomedicine and – to encourage and enable transnational collaboration between academic research (public and private partnersi.e. research teams from universities, higher education institutions, public research institutions) and clinical/public health research (research teams from hospital, healthcare settings and other healthcare organisations) or R&D activities from industrial enterprises (all size).  The participation of Medical Doctors and clinicians is strongly encouraged. SMEs (Small and Medium-size Enterprises) are also strongly encouraged to participate. #NANOTECMEC_E4H Instituto de Salud Carlos III European Health and Digital Executive Agency (HaDEA) ANR, the French National Research Agency https://lnkd.in/dJgz6Zdi 

Impact Assessments within the Health, Well-being and Life Sciences Sector   Kada’s recent evaluation of the University of Cambridge’s pioneering Innovation Centre for Molecular Digital Chemistry sits within our portfolio of evaluation work in the health, well-being and life sciences sector. Kada has now worked with MedCity, the South London Academic Health Science Network and UK Advanced Therapies on various programmes include three rounds of collaborative programmes ‘Collaborate to Innovate’ and ‘Confidence in Collaboration’ and a digital health accelerator. We also evaluated an accelerator at the Advanced Well-Being Research Centre for Sheffield Hallam University, completed an evaluation for NHS England of a digital health technology programme and, for South Yorkshire Mayoral Combined Authority, undertook a health and well-being assets study. Kada has led several med-tech cluster studies too.    The collaborative programmes have fostered partnerships between some of the UK’s leading life science researchers and SMEs at the forefront of digital and scientific advances and innovations in health, well-being and life sciences. As part of these projects the Kada team have spoken to a range of academics, entrepreneurs and SMEs whose work is assisting with world leading developments for the prevention and treatment of life limiting diseases and conditions including Parkinson’s, motor neuron disease, different forms of cancer and dementia.   Our work has involved telling the story behind the collaborations, reviewing the delivery of programmes and quantifying their actual and potential economic, health and wider benefits. For instance many projects have resulted in follow-on collaborations and/or secured subsequent commercial or research investment.     We have recently been awarded a new commission for a world leading university life science institution to evaluate collaborations between SMEs, researchers, and large pharmaceutical companies in their pursuit of life changing treatments.   To find out more please contact Pat at pat@kadaresearch.co.uk #lifesciences #kada #wellbeing

BostonGene had the honor to welcome a delegation from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung) in our laboratory. A big thank you to the German Consulate Boston and the amazing LAURA UDDEN for organizing. Briefly, the Directorate-General 2 of the Federal Ministry is entitled "European and International Cooperation in Education and Research" – and responsible for the governance and development of Germany's international cooperation in education and research. The Division 213 (our visitors) is coordinating collaborations with North- and South America. Undersecretary Vivien Baganz, who leads the Division 213, and Jill Theuring from her division, alongside our Consul General Dr. Sonja Kreibich and the senior science and economic advisor Yannic Arnold, joined our VP of Product Development Alexander Bagaev and Director of Immunology and Immunoprofiling Michael Goldberg for a tour through the laboratory and a focused discussion. Topics included: - Technology transfer and translation from development to clinical practice - Health data utilization and data- and AI-based diagnostics - Consent management including use for research, and recall when new therapies become available - Abstraction of electronic patient records to streamline physician time and much more... It was a pleasure and honor meeting you and we hope our perspectives were valuable. German consulate Boston: https://lnkd.in/ec2GiDch Organization of the BMBF: https://lnkd.in/esvCAQEW BostonGene Bundesministerium für Bildung und Forschung #healthdata #Dataforhealth #datautilization #diagnostics #biomarker #digitalization #GDNG #precisionmedicine #precisiononcology #policymakers #medicaldata

We are thrilled to announce the four research themes for our 2025 Challenge Programme: 1) The NNF Grand AI Challenge 2) Ectopic fat and cardiometabolic disease, 3) Interactions of infectious diseases & CMD, and 4) Heterogeneity in biomanufacturing. This initiative continues our commitment to addressing some of the most pressing societal and planetary challenges of our time. Are you the right person to help solve these challenges? Watch a set of short films and explore the vision behind our Challenge Programme here:  https://lnkd.in/dX2KKVT4 

"Exciting Nanomedicine Opportunity in Europe! ERA4Health has announced a new call, focusing on innovative research projects in the field of #nanomedicine. More specifically, it targets: a) Regenerative Medicine b) Diagnostics c) Nanotherapy The primary goal of this call is to promote and facilitate translational (and transnational) collaboration among academic research partners, public research organizations, as well as clinical and public health research teams working in hospital settings (including the Laboratory of Nanomedicine at ICS Maugeri SpA Società Benefit ;-) ). It also extends to R&D activities within industrial enterprises, regardless of their size (though additional conditions may be added in the final call). The collective objective of this call is to develop a new generation of nano-enabled tools for medical applications. This call presents a tremendous opportunity for the entire community to contribute to the advancement of nanomedicine. #Europeancall #ResearchOpportunity #researchproject #breastcancer

We’re really excited about this one… We’ve just been selected, with our core collaborator Sara Singer from Stanford University School of Medicine, for a National Academy of Medicine Healthy Longevity Catalyst Award, for a new project that builds on our work with the Building H Index: "Reimagining Product Regulation by Quantifying the Economic Externalities of Commercial Influences on Health Behaviors." The award will enable us to analyze the health impacts of selected companies by linking influences on customer health behaviors, to the changes in disease risk attributed to those behaviors, to the annual costs associated with those diseases. The work is inspired by research done at the Impact-Weighted Accounts project at Harvard Business School and the ongoing methodological development of the International Foundation For Valuing Impacts (IFVI), which have been developing models for measuring and valuing in monetary terms the societal impact of corporations as part of a re-imagination of financial and sustainability reporting. We’re all excited to move forward on this project and thrilled that we were one of only 20 US awardees selected from a pool of 500 applicants. https://lnkd.in/en3Xsn3n